| Description | Moxilubant is a small molecule leukotriene B4 receptor 1 (LTB4R) antagonist for the treatment of immune system disorders, skin and musculoskeletal disorders, and may be used in studies of psoriasis and rheumatoid arthritis. |
| In vitro | Moxilubant以2-4 nM的效能抑制LTB4信号传导。[1] |
| In vivo | Moxilubant（口服，每日一至两次，100至500毫克，持续7天）对LTB4途径的抑制效果至少达75%（150毫克）且当剂量达到300毫克时，途径抑制效果可达100%。[1] |
| molecular weight | 455.59 |
| Molecular formula | C26H37N3O4 |
| CAS | 146978-48-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Grönke L, et al. Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(2):409-417. |